ClinicalTrials.Veeva

Menu

Phosphatidylethanol and Other Ethanol Consumption Markers

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Enrolling

Conditions

Alcohol Consumption
Healthy Volunteer

Treatments

Other: Alcohol (Ethanol)

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06747364
R01AA022361 (U.S. NIH Grant/Contract)
STUDY00000887

Details and patient eligibility

About

This study is intended to help the investigators understand how a biomarker found in the blood may be used to better identify the quantity and different patterns of alcohol use.

The investigators hope that the results of this study will help identify the uses of alcohol-use markers in the blood in future alcohol prevention and treatment programs. It is hoped that the information learned from this study will benefit other people in the future.

The study participants will come into the lab and will (1) consume alcohol in the lab designed to produce a peak blood alcohol concentration of 0.06% and have blood collected over 6 hours followed by abstinence for 10 days to give a small blood sample 4 times and (2) to give a small amount of blood 5 times within 28 days (naturalistic drinking) and provide answers about alcohol use.

Full description

The study goal is to account for individual differences in biological variables likely influencing Phosphatidylethanol (PEth) formation to determine the extent to which the investigators can improve their ability to characterize alcohol consumed previously. Investigators propose three experiments that combine: (a) controlled human laboratory studies in vivo, (b) clinical laboratory studies of important enzymatic and biological variables measured ex vivo, and (c) the creation and testing of regression models to predict drinking during a naturalistic observational study using PEth levels and key biological variables identified in the lab.

Aim 1 is an in vivo pharmacokinetic study that whereby participants will consume a dose of alcohol to achieve a target blood alcohol concentration of 0.06%. Blood samples will be collected repeatedly during a 6-hour period to characterize blood/breath alcohol concentrations and PEth syntheses. Then PEth elimination half-life will be characterized across a 10-day period while remaining alcohol abstinent outside the lab.

In Aim 2, alcohol-free blood collected from Aim 1 will be examined ex vivo to characterize key biological variables (e.g., enzyme activity, red blood cell count, precursor levels) involved in PEth synthesis and elimination. Regression formulas will evaluate these variables for their ability to explain the previously unexplained between-subject differences in the PEth levels formed after the same amount of alcohol is consumed.

Finally, in Aim 3, regression equations will be used to evaluate the value of using these biological/enzyme variables to improve (above and beyond that of PEth alone) the prediction of naturalistic drinking self-reported by participants over a 28-day period.

Enrollment

80 estimated patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. are ≥ 21 years old;
  2. are height and weight proportionate (body mass index 18-30); and
  3. report drinking on > 1 days in the last month, with at least one day equal to at least achieving ~0.06% BAC.

Exclusion criteria

  1. have significant current or predicted alcohol withdrawal symptoms (CIWA-AR scores ≥ 10);
  2. are currently in alcohol treatment;
  3. have substance use disorder (except nicotine, and/or caffeine);
  4. have a medical condition that would contraindicate participation (a positive urine pregnancy test, self-reported scheduled surgery or liver disease);
  5. are currently breast feeding;
  6. have a presence of a DSM-5 psychiatric disorder with symptoms of psychosis and/or delirium; or
  7. are unable to comprehend the informed consent process or study instructions.

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

80 participants in 1 patient group

In Lab alcohol consumption followed by 10 days of abstinence and then 28-days naturalistic drinking
Experimental group
Description:
Up to 40 Healthy volunteers will consume alcohol in the lab designed to produce a peak blood alcohol concentration of 0.06% and have blood collected over 6 hours. Followed by 10 days of abstinence and 4 visits to provide 1 blood sample each time. These 40 participants will then consume alcohol as usual outside the laboratory for 28 days and blood will be collected weekly (Day 0, Day 7, Day 14, 21 and 28). A second cohort of 40 participants will then undergo the naturalistic portion with blood collected on Days 0, Day 7, Day 14, 21 and 28.
Treatment:
Other: Alcohol (Ethanol)

Trial contacts and locations

2

Loading...

Central trial contact

Nathalie Hill-Kapturczak, PhD; Donald Dougherty, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems